Android app on Google Play

Amarin (AMRN) Receives Additional Patent Allowance for Vascepa

March 7, 2013 8:00 AM EST Send to a Friend
Amarin Corporation plc (Nasdaq: AMRN) announced that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/614,111titled "Stable Pharmaceutical Compositions and Methods of Using the Same." This application includes claims intended to protect the proposed Vascepa® (icosapent ethyl) indication based on Amarin's Phase 3 ANCHOR clinical trial results. In late February, Amarin filed a Supplemental New Drug Application for the Vascepa ANCHOR indication with the U.S. Food and Drug Administration (FDA), and expects an FDA action date on the application before the end of 2013.

A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2030. Amarin plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, after issuance of the patent and the anticipated approval of Vascepa in the ANCHOR indication.

The claims in this allowed application relate to the planned Vascepa ANCHOR indication and cover methods of treating mixed dyslipidemia through the daily administration of 2500 mg to 5000 mg of highly pure EPA to a subject on any statin therapy.

This application is part of an expanding patent portfolio for Amarin with 19 patent applications now either issued or allowed with the USPTO and over 30 additional applications pending in the United States. Amarin is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the United States, including the application for Amarin's MARINE method of use patent in Europe for which Amarin has announced receipt of an Intention to Grant letter.




You May Also Be Interested In


Related Categories

Corporate News, FDA, Litigation

Add Your Comment